Sales and Marketing
CHMP recommends approval of dupixent for children with severe asthma
January 31, 2022 Sales and Marketing
The EMA’s CHMP has adopted a positive opinion recommending the extension of the approval of Dupixent (dupilumab) for children with …
Ascletis begins Phase III trial into bevacizumab for treatment of recurrent glioblastoma
January 24, 2022 Sales and Marketing
Ascletis Pharma has announced the dosing of the first patient in the Phase III registration clinical trial of ASC40, combined …
Pfizer: Annual COVID shots preferable to frequent boosters
January 24, 2022 Sales and Marketing
Pfizer CEO Albert Bourla has commented that an annual COVID-19 vaccine would be preferable to more frequent booster shots in …
NICE expands guidance for lokelma in adult patients with persistent hyperkalaemia
January 24, 2022 Sales and Marketing
NICE have updated the Technology Appraisal Guidance (TAG) for Lokelma (sodium zirconium cyclosilicate SZC) in the treatment of adult patients …
Veklury obtains FDA approval for COVID-19 outpatients
January 24, 2022 Sales and Marketing
The FDA has granted expedited approval of a supplemental new drug application (sNDA) for Veklury (remdesivir) for he treatment of …
Neurimmune and Ono Pharmaceutical collaborate to research neurodegenerative diseases
January 17, 2022 Sales and Marketing
Neurimmune AG has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical. The companies aim to focus on creating …
NICE draft guidance recommends new treatment for rare liver condition
January 17, 2022 Sales and Marketing
On Friday 14 January, NICE published a final draft Highly Specialised Technologies guidance, recommending odevixibat in line with its marketing …
FDA places Alzheimer’s therapeutic IND Application on hold
January 17, 2022 Sales and Marketing
The FDA has placed a hold on the Investigational New Drug (IND) application for DNL919, indicating they will provide an …
COVID-19 self-isolation cut to five full days in England
January 17, 2022 Sales and Marketing
The minimum self-isolation period for people testing positive for COVID-19 in England has been cut from seven days to five …
Trial finds new CAR T-cell therapy is effective at killing cancer cells
January 10, 2022 Sales and Marketing
A Phase I clinical trial funded by the NIHR Invention for Innovation (i4i) programme, and supported by the NIHR UCLH …
European Commission approves Lumykras for lung cancer patients
January 10, 2022 Sales and Marketing
The European Commission (EC) has granted conditional marketing authorisation for Lyumykras (sotorasib), a first-in-class KRAS inhibitor, for the treatment of …
FDA approval of QUVIVIQ (daridorexant) for the treatment of insomnia
January 10, 2022 Sales and Marketing
Idorsia Ltd has announced the FDA approval of QUVIVIQ™ (daridorexant) 25 mg and 50 mg for the treatment of adult …
Phase III trial into lebrikizumab shows positive results for atopic dermatitis patients
January 10, 2022 Sales and Marketing
Almirall has reported positive results from their Phase III trial into lebrikizumab, which demonstrated significant improvement and itch relief when …
Positive CHMP opinion for sickle cell disease anaemia tablet
December 20, 2021 Sales and Marketing
Global Blood Therapeutics (GBT) have announced the CHMP adopted a positive opinion recommending marketing authorisation for Oxbryta® (vocelotor) tablets. Oxbryta …
FDA approval of Tezspire for severe asthma
December 20, 2021 Sales and Marketing
Tezpire (tezepelumab-ekko), manufactured by AstraZeneca and Amgen, has been approved in the US for the add-on maintenance treatment of adult …
Latest content
Recruitment experts hired in search for new CGT Catapult chief
November 14, 2026
Envirogen secures place on NHS Scotland reverse osmosis framework
November 13, 2026
